Arcus Biosciences, Inc.

RCUS · NYSE

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders28.8%

Institutions74.9%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$247.00M	$258.00M	$117.00M	$112.00M	$382.88M	$77.52M	$15.00M	$8.35M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$386.00M	-$330.00M	–	–	$54.25M	-$124.23M	-$88.71M	-$54.86M
Operating income as a percentage of revenue.	-156.3%	-127.9%	–	–	14.2%	-160.3%	-591.4%	-656.8%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$353.00M	-$283.00M	-$307.00M	-$267.00M	$52.83M	-$122.86M	-$84.71M	-$49.59M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.29	$-3.14	–	–	–	–	–	–
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.29	$-3.14	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$222.00M	$150.00M	$127.00M	$206.00M	$147.91M	$173.41M	$57.94M	$71.06M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.14B	$1.15B	$1.09B	$1.34B	$1.59B	$772.29M	$203.11M	$274.93M
Everything the company owes — debt, unpaid bills, and other obligations.	–	–	–	–	$750.45M	$269.99M	$39.27M	$39.98M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$631.00M	$485.00M	$462.00M	$657.00M	$841.45M	$502.30M	$163.84M	$234.94M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$482.00M	-$170.00M	-$306.00M	$438.00M	-$256.17M	$111.17M	-$73.46M	-$43.00M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$2.00M	$6.00M	$24.00M	$6.00M	$26.08M	$3.06M	$1.93M	$3.74M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$484.00M	-$176.00M	-$330.00M	$432.00M	-$282.25M	$108.11M	-$75.39M	-$46.74M

	You	Peer avg
Revenue Growth	-74.4%	+65.7%
ROE	-90.8%	-41.7%

Arcus Biosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison